InsiderTrades.com logo
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.

Aron English Biography and Net Worth

Insider of Anebulo Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Aron R. English has been a member of our board of directors since June 2020. He is the founder and has served as the President and Portfolio Manager of 22NW, LP, a Seattle-based value fund specializing in small and microcap investments with a multi-year investment horizon, since August 2014. Previously, Mr. English served as the director of research at Meson Capital Partners LLC, an investment firm, from January 2014 to August 2014. Prior to that, he served as director of research at RBF Capital, LLC, a provider of wealth management and financial services, from September 2010 until December 2013, after initially serving as a research analyst at the firm from September 2008 to September 2010. Mr. English served as a research assistant at McAdams Wright Ragen Inc., an investment firm, from March 2006 until September 2008. Mr. English earned his B.A. degree in English Literature with honors from the University of Washington, and holds the Chartered Financial Analyst (CFA) designation.

What is Aron R. English's net worth?

The estimated net worth of Aron R. English is at least $2.31 million as of September 17th, 2024. Mr. English owns 1,456,827 shares of Anebulo Pharmaceuticals stock worth more than $2,314,024 as of November 16th. This net worth evaluation does not reflect any other investments that Mr. English may own. Learn More about Aron R. English's net worth.

How do I contact Aron R. English?

The corporate mailing address for Mr. English and other Anebulo Pharmaceuticals executives is , , . Anebulo Pharmaceuticals can also be reached via phone at 512-598-0931 and via email at [email protected]. Learn More on Aron R. English's contact information.

Has Aron R. English been buying or selling shares of Anebulo Pharmaceuticals?

Aron R. English has not been actively trading shares of Anebulo Pharmaceuticals in the last ninety days. Most recently, on Friday, December 17th, Aron R. English bought 400 shares of Anebulo Pharmaceuticals stock. The stock was acquired at an average cost of $6.59 per share, with a total value of $2,636.00. Learn More on Aron R. English's trading history.

Aron R. English Insider Trading History at Anebulo Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2021Buy400$6.59$2,636.00View SEC Filing Icon  
12/14/2021Buy412$5.89$2,426.68View SEC Filing Icon  
12/2/2021Buy13,836$5.30$73,330.80View SEC Filing Icon  
See Full Table

Aron R. English Buying and Selling Activity at Anebulo Pharmaceuticals

This chart shows Aron R English's buying and selling at Anebulo Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anebulo Pharmaceuticals Company Overview

Anebulo Pharmaceuticals logo
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Read More

Today's Range

Now: $1.59
Low: $1.52
High: $1.59

50 Day Range

MA: $1.91
Low: $1.48
High: $3.08

2 Week Range

Now: $1.59
Low: $1.46
High: $3.30

Volume

2,443 shs

Average Volume

6,759 shs

Market Capitalization

$41.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.